## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.91 indicates fundamental undervaluation. Quality metrics strong (ROE 31%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($61.21)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 10)

**1. DXCM Deadline: DXCM Investors with Losses in Excess of $100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit**
- Source: Morningstar | 20251215T221654 | Bearish | Relevance: 100%
- Rosen Law Firm is reminding investors of DexCom, Inc. (NASDAQ: DXCM) who purchased securities between July 26, 2024, and September 17, 2025, of the upcoming December 29, 2025, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems and overstated their reliability, leading to potential health risks and increased regulatory scrutiny. Investors with losses exceeding $100K are encouraged to contact the law firm to join the class action.

**2. Lost Money on DexCom, Inc.(DXCM)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky**
- Source: WLNS 6 News | 20251215T210820 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has filed a class action securities lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who allegedly suffered losses due to securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly downplayed. Investors have until December 26, 2025, to request to be appointed lead plaintiff.

**3. Securities Lawsuit Alert: DexCom, Inc. (DXCM) - Contact Levi & Korsinsky Before December 26, 2025**
- Source: KTLA | 20251215T180759 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has announced a securities lawsuit against DexCom, Inc. (NASDAQ: DXCM) for shareholders who suffered losses due to alleged securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly concealed. Affected shareholders are encouraged to contact Levi & Korsinsky to learn about their rights for potential recovery before December 26, 2025.

**4. Lost Money on DexCom, Inc.(DXCM)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky**
- Source: GlobeNewswire | 20251215T155000 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has filed a class action lawsuit against DexCom, Inc. (DXCM) on behalf of investors who suffered losses due to alleged securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims that DexCom made material, unauthorized design changes to its glucose monitoring products, the G6 and G7, rendering them less reliable and posing health risks, while the company allegedly downplayed these issues. Investors have until December 26, 2025, to request to be appointed as lead plaintiff.

**5. DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm**
- Source: GlobeNewswire | 20251215T150811 | Bearish | Relevance: 100%
- The Schall Law Firm is reminding investors of a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) for alleged securities fraud. The lawsuit claims DexCom made false and misleading statements regarding unauthorized changes to its G6 and G7 systems, leading to reliability issues and health risks for users. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, are encouraged to contact the firm before December 26, 2025, to participate in the lawsuit.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 11.6% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +11%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.8B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 26.5 |
| Current P/E | 31.8 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.9% to 3.7% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.3pp (needs >4.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.4% shows strong absolute momentum above own 20MA. Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (0.56), confirming momentum. RSI neutral at 55. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.70% (CS: 65) | Neutral |
| RSI_14 | 54.8 | Neutral |
| MACD Histogram | 0.56 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 0.884x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $65.73
- **Stop Loss:** $61.21 (6.9% risk)
- **Target:** $74.77 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 265
- **Position Value:** $17,418.45
- **Portfolio %:** 17.42%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*